Frequency of Transition From Stage A to Stage B Heart Failure After Initiating Potentially Cardiotoxic Chemotherapy
| Autor: | Cynthia K. Suerken, Ralph B. D'Agostino, Zanetta S. Lamar, Alexandra Thomas, Dalane W. Kitzman, Jennifer H. Jordan, Deanna N. Jones, Giselle C. Meléndez, W. Gregory Hundley |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Heart Diseases Anthracycline medicine.medical_treatment 030204 cardiovascular system & hematology Cardiotoxins Article 03 medical and health sciences 0302 clinical medicine Trastuzumab Neoplasms Internal medicine Humans Medicine Stage (cooking) health care economics and organizations Heart Failure Cardiotoxicity Chemotherapy business.industry Middle Aged medicine.disease 030220 oncology & carcinogenesis Heart failure Disease Progression Cardiology Female Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | JACC: Heart Failure. 6:1023-1032 |
| ISSN: | 2213-1779 |
| DOI: | 10.1016/j.jchf.2018.08.005 |
| Popis: | OBJECTIVE: To determine the prevalence of American Heart Association and American College of Cardiology Foundation (AHA/ACCF) heart failure (HF) Stages after initiating potentially cardiotoxic chemotherapy. BACKGROUND: For individuals receiving potentially cardiotoxic chemotherapy, the frequency of transitioning from Stage A to more advanced HF Stages is not well described. METHODS: In 143 Stage A HF patients with breast cancer, lymphoma/leukemia, renal cell carcinoma, or sarcoma prior to and then three, six, and 12–24 months after initiating potentially cardiotoxic chemotherapy, we obtained blinded cardiovascular magnetic resonance measures of left ventricular ejection fraction (LVEF). RESULTS: Three months after initiating potentially cardiotoxic chemotherapy, 18.9% of patients transitioned from Stage A to Stage B HF. Eight-three percent and 80% of patients with Stage A HF at three months respectively exhibited Stage A HF at six and 12–24 months; 68% and 56% of those with Stage B HF at three months respectively exhibited Stage B HF at six and 12–24 months (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|